CRO

Quotient doubles formulation capacity; WuXi raising $80M for manufacturing;

> Quotient Clinical is doubling its formulation development capacity with the construction of a new, 8,000-square-foot manufacturing facility. News

> WuXi PharmaTech ($WX) is selling a 6% stake in its SynTheAll manufacturing unit for $80 million. Story

> Catalent says it has resolved some issues at a North Carolina plant that surfaced in a routine FDA inspection. More